Pasithea Therapeutics to present initial Phase 1/1b PAS-004 data in adult NF1 trial at 2026 European Neurofibromatosis Conference
KTTA•Conference presentation planned for initial PAS-004 data
Pasithea Therapeutics flagged initial Part A clinical data from its ongoing Phase 1/1b trial of PAS-004 in adults with neurofibromatosis type 1 for presentation at the European Neurofibromatosis Conference in Vienna on Nov. 12-14, 2026.
The results have not yet been publicly disclosed.
The company plans to present cutaneous neurofibromas data in an oral session on Nov. 13, 2026.
Plexiform neurofibromas data is slated for a poster session on Nov. 12.
Pasithea plans a follow-up release with detailed findings at the time of presentation.
